What's new

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

Mar 12, 2025 - 16:15
 0
Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised
Read More

Tags:

Previous Article

Ono pays $280M to license Ionis rare disease drug

Next Article

Fraunhofer ISE: Monocrystalline modules underperformed by 1.2% in 2024

Related Posts

Veterinary medicines European public assessment report (EPAR): Nobilis Multriva REOm, avian reovirus vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report ...

Mar 7, 2025  0

Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 March 2025, 15:30 (CET) to 5 March 2025, 17:00 (CET)

Clinical Trials Information System (CTIS) bitesize talk...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 20, 2025  0